Fund shareholders of MoonLake Immunotherapeutics
ISIN KY61559X1045 · Cayman Islands
- Fund shareholders
- 34
- Of which ETFs
- 13 21 other funds
- Value held
- ≈ 34.3M $ 34.2M $ · 36.7K €
34 funds hold this company. This table lists the 33 that declare it in a regulatory filing. 1 more fund publishes its holdings in its own report. It is not in the table.
| Fund | Shares | Value | Weight in fund | |
|---|---|---|---|---|
| T. Rowe Price Health Sciences Fund, Inc. T. ROWE PRICE HEALTH SCIENCES FUND, INC. | 887,029 | 16.5M $ | 0.15 % | as of Mar 31, 2026 ↗ |
| Select Biotechnology Portfolio Fidelity Select Portfolios | 143,558 | 2.5M $ | 0.05 % | as of Feb 28, 2026 ↗ |
| JNL Multi-Manager Small Cap Value Fund JNL Series Trust | 109,447 | 2M $ | 0.12 % | as of Mar 31, 2026 ↗ |
| VANGUARD HEALTH CARE INDEX FUND VANGUARD WORLD FUND | 95,724 | 1.7M $ | 0.01 % | as of Feb 28, 2026 ↗ |
| iShares ESG Aware MSCI USA Small-Cap ETF iShares Trust | 86,030 | 1.5M $ | 0.06 % | as of Feb 28, 2026 ↗ |
| Nomura Healthcare Fund Delaware Group Equity Funds IV | 80,000 | 1.5M $ | 0.22 % | as of Mar 31, 2026 ↗ |
| ALPS Medical Breakthroughs ETF ALPS ETF TRUST | 63,143 | 1.1M $ | 0.80 % | as of Feb 28, 2026 ↗ |
| Victory Small Cap Stock Fund Victory Portfolios III | 59,698 | 977.9K $ | 0.11 % | as of Apr 30, 2026 ↗ |
| Invesco Dorsey Wright Healthcare Momentum ETF Invesco Exchange-Traded Fund Trust | 58,091 | 951.5K $ | 0.79 % | as of Apr 30, 2026 ↗ |
| T. Rowe Price Health Sciences Portfolio T. ROWE PRICE EQUITY SERIES, INC. | 54,070 | 1M $ | 0.15 % | as of Mar 31, 2026 ↗ |
| Fidelity Nasdaq Composite Index Fund Fidelity Concord Street Trust | 41,878 | 733.3K $ | 0.00 % | as of Feb 28, 2026 ↗ |
| Nuveen ESG Small-Cap ETF NuShares ETF Trust | 33,673 | 551.6K $ | 0.04 % | as of Apr 30, 2026 ↗ |
| Fidelity Nasdaq Composite Index ETF Fidelity Commonwealth Trust | 32,328 | 566.1K $ | 0.01 % | as of Feb 28, 2026 ↗ |
| Optimize Strategy Index ETF Advisor Managed Portfolios | 24,419 | 455.2K $ | 0.22 % | as of Mar 31, 2026 ↗ |
| Health Sciences Trust John Hancock Variable Insurance Trust | 21,385 | 398.6K $ | 0.18 % | as of Mar 31, 2026 ↗ |
| Virtus Biotech Clinical Trials Etf ETFis Series Trust I | 18,661 | 305.7K $ | 0.82 % | as of Apr 30, 2026 ↗ |
| EQ/T.Rowe Price Health Sciences Portfolio EQ Advisors Trust | 16,351 | 304.8K $ | 0.19 % | as of Mar 31, 2026 ↗ |
| Fidelity MSCI Health Care Index ETF FIDELITY COVINGTON TRUST | 14,568 | 238.6K $ | 0.01 % | as of Apr 30, 2026 ↗ |
| T. Rowe Price Health Care ETF T. Rowe Price Exchange-Traded Funds, Inc. | 9,719 | 181.2K $ | 0.89 % | as of Mar 31, 2026 ↗ |
| VANGUARD ESG U.S. STOCK ETF VANGUARD WORLD FUND | 7,213 | 126.3K $ | 0.00 % | as of Feb 28, 2026 ↗ |
| Victory Extended Market Index Fund Victory Portfolios III | 7,203 | 118K $ | 0.02 % | as of Apr 30, 2026 ↗ |
| BlackRock Advantage SMID Cap Fund, Inc. BlackRock Advantage SMID Cap Fund, Inc. | 6,836 | 127.4K $ | 0.02 % | as of Mar 31, 2026 ↗ |
| Health Sciences Portfolio PACIFIC SELECT FUND | 3,966 | 73.9K $ | 0.02 % | as of Mar 31, 2026 ↗ |
| Blackstone Alternative Multi-Strategy Fund Blackstone Alternative Investment Funds | 3,800 | 70.8K $ | 0.00 % | as of Mar 31, 2026 ↗ |
| JNL/DFA U.S. Small Cap Fund JNL Series Trust | 2,307 | 43K $ | 0.01 % | as of Mar 31, 2026 ↗ |
| Clearwater Select Equity Fund Clearwater Investment Trust | 1,977 | 36.9K $ | 0.01 % | as of Mar 31, 2026 ↗ |
| iShares MSCI World Small-Cap ETF iShares Trust | 1,875 | 32.8K $ | 0.00 % | as of Feb 28, 2026 ↗ |
| BlackRock Advantage SMID Cap V.I. Fund BlackRock Variable Series Funds, Inc. | 996 | 18.6K $ | 0.01 % | as of Mar 31, 2026 ↗ |
| Harbor Active Small Cap Growth ETF Harbor ETF Trust | 826 | 13.5K $ | 0.37 % | as of Apr 30, 2026 ↗ |
| T. Rowe Price Innovation Leaders ETF T. Rowe Price Exchange-Traded Funds, Inc. | 544 | 10.1K $ | 0.07 % | as of Mar 31, 2026 ↗ |
| Knights of Columbus U.S. ALL CAP INDEX FUND ADVISORS' INNER CIRCLE III | 244 | 4K $ | 0.00 % | as of Apr 30, 2026 ↗ |
| E*TRADE No Fee Total Market Index Fund E Trade Trust | 10 | 163.8 $ | 0.00 % | as of Apr 30, 2026 ↗ |
| A&P LIFESCIENCE FUND, FI WELZIA MANAGEMENT, SGIIC, S.A. | 36.7K € | 1.00 % | as of Dec 31, 2025 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| A&P LIFESCIENCE FUND, FI WELZIA MANAGEMENT, SGIIC, S.A. | 1.00 % | as of Dec 31, 2025 ↗ |
| T. Rowe Price Health Care ETF T. Rowe Price Exchange-Traded Funds, Inc. | 0.89 % | as of Mar 31, 2026 ↗ |
| Virtus Biotech Clinical Trials Etf ETFis Series Trust I | 0.82 % | as of Apr 30, 2026 ↗ |
| ALPS Medical Breakthroughs ETF ALPS ETF TRUST | 0.80 % | as of Feb 28, 2026 ↗ |
| Invesco Dorsey Wright Healthcare Momentum ETF Invesco Exchange-Traded Fund Trust | 0.79 % | as of Apr 30, 2026 ↗ |
| Harbor Active Small Cap Growth ETF Harbor ETF Trust | 0.37 % | as of Apr 30, 2026 ↗ |
| Nomura Healthcare Fund Delaware Group Equity Funds IV | 0.22 % | as of Mar 31, 2026 ↗ |
| Optimize Strategy Index ETF Advisor Managed Portfolios | 0.22 % | as of Mar 31, 2026 ↗ |
| EQ/T.Rowe Price Health Sciences Portfolio EQ Advisors Trust | 0.19 % | as of Mar 31, 2026 ↗ |
| Health Sciences Trust John Hancock Variable Insurance Trust | 0.18 % | as of Mar 31, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Shareholders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q2 | 32 | -4 | 1,887,569 | -21.4 % |
| 2026Q1 | 36 | -19 | 2,400,998 | -50.8 % |
| 2025Q4 | 55 | -59 | 4,883,886 | -59.5 % |
| 2025Q3 | 114 | +8 | 12,057,051 | -8.0 % |
| 2025Q2 | 106 | 0 | 13,111,725 | +0.1 % |
| 2025Q1 | 106 | -2 | 13,098,345 | +14.1 % |
| 2024Q4 | 108 | +9 | 11,484,739 | +24.8 % |
| 2024Q3 | 99 | -16 | 9,203,952 | -4.2 % |
| 2024Q2 | 115 | +13 | 9,604,828 | +7.7 % |
| 2024Q1 | 102 | +4 | 8,914,871 | -3.9 % |
| 2023Q4 | 98 | 9,280,556 |
Cite this page
Titelia. "Fund shareholders of MoonLake Immunotherapeutics". https://titelia.com/en/stocks/moonlake-immunotherapeutics-KY61559X1045